Puma Biotechnology (PBYI) Receivables - Other (2012 - 2019)

Puma Biotechnology (PBYI) reported Receivables - Other of $9.9 million for Q1 2019, up 743.57% quarter-over-quarter from $1.2 million in Q4 2018.

Puma Biotechnology (PBYI) Receivables - Other (2012 - 2019) Analysis & Trends

Puma Biotechnology has reported Receivables - Other for 5 years, with the latest figure at $9.9 million in Q1 2019.

For the quarter ending Q1 2019, Receivables - Other changed N/A year-over-year to $9.9 million; the trailing twelve-month figure through Mar 2019 stood at $9.9 million (changed N/A YoY), and the FY2018 full-year result was $1.2 million, changed N/A from the prior year.
Receivables - Other for Q1 2019 stood at $9.9 million, up from $1.2 million in the prior quarter.
The five-year high for Receivables - Other was $11.2 million in Q3 2018, with the low at $1.2 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Puma Biotechnology	384.39 Mn	282.84 Mn	34.39 Mn

Download Data